Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neurofibromatosis 1 7Neurofibroma, Plexiform 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 2Recurrence 1Pain 1Neoplasms 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Melanoma 1Gallbladder Neoplasms 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Gemcitabine 6Cisplatin 6Bortezomib 6venetoclax 5elotuzumab 4isatuximab 3blinatumomab 3Vincristine 3Radiotherapy 3Prednisone 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2ixazomib 2dexamethasone 21-phosphate 2cabazitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × AZD 6244 × Clear all
NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
57 enrolled
Gastrointestinal

Gallbladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡